EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

By A. Heidenreich, J. Bellmunt, Michel Bolla, Steven Joniau, M. Mason, V. Matveev, N. Mottet, H. Schmid, T. H. van der Kwast, Thomas Wiegel and 1 more. European Urology, 2011

1,458 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. (2012, background): “Pelvic lymphadenectomy (PLND) is an essential staging procedure for the detection of nodalmetastases in prostate cancer (PCa) [1].”
Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. (2012, neutral): “International guidelines support opportunistic prostatespecific antigen (PSA) screening in well-informed patients and recommend a baseline PSA at 40 yr of age [1–3].”
Active surveillance for prostate cancer: a systematic review of the literature. (2012, background): “The American Urological Association, European Association of Urology, and the National Comprehensive Care Network have all published guidelines for the treatment of localized PCa that include AS [3–5].”
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014, background): “The most recent summary of the European Association of Urology (EAU) guidelines on prostate cancer (PCa) was published in 2011 [1].”